On March 09, 2022, the Moscow Arbitration Court satisfied the claim of Zentiva Pharma against Farmatun-1, Dinamika and MC Dinamika for the protection of patent rights in relation to Dolphin nasal washing device (utility model No.151,829). The Defendants were forbidden to sell, offer for sale and store for these purposes their medical product «Duolor».
Until 2018, Defendants were engaged in the production of devices and nasal washing products under the brand name «Dolphin» for Zentiva Pharma. After the transfer of production, they released under their brand a product «Duolor» similar to “Dolphin».
Defendants insisted that their device is manufactured according the utility model No 196,933 and does not contain «a dispenser having an axial channel» described in Zentiva’s patent. But this argument was refuted by the patent examination. Further, the Сourt noted that the Defendants’ reference to the later utility model No. 196933 does not influence on the consideration of this dispute regarding infringement of the Zentiva’s patent.
Thus, the Court found that the Defendants’ product «Duolor» contains every feature of the plaintiff’s utility model, and a permission of the patent owner for production and sale has not been obtained. The Court satisfied the claim and recovered from the defendants the costs of the examination.
In 1995, the Eurasian Patent Convention (EAPC) was established to create a unified patent space,…
Olga Gribanova and Eduard Shablin of Patentica were in attendance at the 76th Asian Patent…
Dear colleagues, we would like to inform you about the weekends and holidays in 2025…
Maria Nilova and Nikolai Kovkov from Patentica recently participated in the AIPLA 2024 Annual Meeting…
Maria Nilova and Nikolai Kovkov from Patentica recently took part in the LES USA-Canada Annual…